Insception Bioscience Inc

Appili Therapeutics is a pharmaceutical company based in Mississauga, ON, focused on developing novel treatments for infectious diseases. They prioritize research and innovation to address unmet medical needs in the field of infectious disease. With a dedicated team of experts, Appili Therapeutics is committed to advancing their pipeline of potential therapies through rigorous clinical trials and regulatory processes. Their mission is to improve patient outcomes and contribute to the global fight against infectious diseases. Generated from their business information

Innovative End-to-End Solutions for Phase 1 Clinical TrialsClinical trial complexity has strikingly escalated during the last decades, including a surge in the number of performed procedures, associated costs, and administrative load. Phase 1 clinical trials pose an especially significant challenge due to the requirements for extensive safety monitoring and correlative testing and the high failure rate of developmental drug candidates. BioPharma Services Inc. offers end-to-end solutions for Phase 1 clinical trials ranging from clinical trial design and execution to data reporting and tabulation and the preparation of a final Clinical Study Report. In addition, we have niche expertise in a number of study areas.

Lucid Psycheceuticals Inc, based in Toronto, Ontario, is a biotech company inspired by psychedelics. Specializing in the development of novel therapeutic solutions for neuro and inflammatory disorders, the team at Lucid is dedicated to addressing unmet clinical challenges with a focus on small molecule drugs. With a strong emphasis on total brain health and environmentally friendly solutions, Lucid Psycheceuticals is at the forefront of creating leading-edge therapeutics. The team consists of highly specialized science experts who are passionately committed to advancing treatments in the fields of inflammatory disorders, neurodegenerative disorders, and mental health. Lucid's groundbreaking work includes the shortlisting of Lucid-201, a molecule proven to be effective in treating major depressive disorder and related psychiatric conditions. Additionally, through the acquisition of exclusive licenses and preclinical data, the company is actively pursuing innovative solutions for neurodegenerative disorders, showcasing their dedication to advancing the field with some of the industry's brightest minds. Generated from the website content